Barclays PLC Acquires 158,188 Shares of Privia Health Group, Inc. (NASDAQ:PRVA)

Barclays PLC raised its position in Privia Health Group, Inc. (NASDAQ:PRVA - Free Report) by 240.3% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 224,018 shares of the company's stock after purchasing an additional 158,188 shares during the quarter. Barclays PLC owned 0.19% of Privia Health Group worth $4,079,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in PRVA. Victory Capital Management Inc. increased its holdings in Privia Health Group by 402.9% in the third quarter. Victory Capital Management Inc. now owns 179,049 shares of the company's stock worth $3,260,000 after purchasing an additional 143,446 shares in the last quarter. GAMMA Investing LLC lifted its position in shares of Privia Health Group by 98.7% during the 3rd quarter. GAMMA Investing LLC now owns 1,701 shares of the company's stock worth $31,000 after buying an additional 845 shares in the last quarter. Dynamic Technology Lab Private Ltd purchased a new position in Privia Health Group in the third quarter worth $1,206,000. Peregrine Capital Management LLC grew its position in shares of Privia Health Group by 11.5% during the 2nd quarter. Peregrine Capital Management LLC now owns 314,190 shares of the company's stock valued at $5,461,000 after acquiring an additional 32,311 shares during the period. Finally, Eventide Asset Management LLC lifted its position in shares of Privia Health Group by 979.2% during the 3rd quarter. Eventide Asset Management LLC now owns 822,438 shares of the company's stock valued at $14,977,000 after buying an additional 746,231 shares during the last quarter. 94.48% of the stock is currently owned by institutional investors and hedge funds.

Privia Health Group Trading Down 0.8 %

NASDAQ PRVA traded down $0.16 during trading on Monday, hitting $19.91. The company had a trading volume of 392,217 shares, compared to its average volume of 841,445. The company's fifty day moving average is $20.30 and its 200-day moving average is $19.16. The company has a market cap of $2.39 billion, a price-to-earnings ratio of 199.12, a price-to-earnings-growth ratio of 5.45 and a beta of 0.83. Privia Health Group, Inc. has a one year low of $15.92 and a one year high of $24.30.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on PRVA. Barclays upped their price target on Privia Health Group from $19.00 to $21.00 and gave the company an "equal weight" rating in a research report on Friday, November 8th. Macquarie began coverage on Privia Health Group in a report on Monday, December 16th. They issued an "outperform" rating and a $25.00 price target on the stock. Robert W. Baird lifted their target price on shares of Privia Health Group from $23.00 to $24.00 and gave the company an "outperform" rating in a research report on Monday, August 26th. Truist Financial increased their target price on Privia Health Group from $24.00 to $27.00 and gave the company a "buy" rating in a research note on Friday, November 8th. Finally, KeyCorp started coverage on Privia Health Group in a research report on Friday, October 11th. They set an "overweight" rating and a $23.00 price objective on the stock. Two investment analysts have rated the stock with a hold rating, twelve have given a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of "Buy" and a consensus price target of $24.80.

Privia Health Group Profile

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.